MX2024012532A - Composiciones de oligonucleótidos y métodos relacionados con las mismas - Google Patents

Composiciones de oligonucleótidos y métodos relacionados con las mismas

Info

Publication number
MX2024012532A
MX2024012532A MX2024012532A MX2024012532A MX2024012532A MX 2024012532 A MX2024012532 A MX 2024012532A MX 2024012532 A MX2024012532 A MX 2024012532A MX 2024012532 A MX2024012532 A MX 2024012532A MX 2024012532 A MX2024012532 A MX 2024012532A
Authority
MX
Mexico
Prior art keywords
present disclosure
oligonucleotide compositions
methods related
oligonucleotides
modifications
Prior art date
Application number
MX2024012532A
Other languages
English (en)
Spanish (es)
Inventor
Genliang Lu
Prashant Monian
Chikdu Shakti Shivalila
Jack David Godfrey
Ian Chandler Harding
Paloma Hoban Giangrande
Tom Liantang Pu
Nayantara Kothari
Subramanian Marappan
Chandra Vargeese
Pachamuthu Kandasamy
Hui Yu
Jayakanthan Kumarasamy
Naoki Iwamoto
Stephany Michelle Standley
Mamoru Shimizu
Timothy Charles Ryan
Jigar Desai
Anthony Lamattina
Milinda Amila Kumara Samaraweera
Wei Liu
Brett Schrand
Original Assignee
Wave Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences Ltd filed Critical Wave Life Sciences Ltd
Publication of MX2024012532A publication Critical patent/MX2024012532A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024012532A 2022-04-15 2024-10-09 Composiciones de oligonucleótidos y métodos relacionados con las mismas MX2024012532A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263331756P 2022-04-15 2022-04-15
US202263397320P 2022-08-11 2022-08-11
US202263411062P 2022-09-28 2022-09-28
US202363454299P 2023-03-23 2023-03-23
PCT/US2023/018742 WO2023201095A2 (en) 2022-04-15 2023-04-14 Oligonucleotide compositions and methods relating thereto

Publications (1)

Publication Number Publication Date
MX2024012532A true MX2024012532A (es) 2024-12-06

Family

ID=88330318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012532A MX2024012532A (es) 2022-04-15 2024-10-09 Composiciones de oligonucleótidos y métodos relacionados con las mismas

Country Status (10)

Country Link
US (1) US20250262235A1 (cg-RX-API-DMAC7.html)
EP (1) EP4507700A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025513847A (cg-RX-API-DMAC7.html)
KR (1) KR20250004787A (cg-RX-API-DMAC7.html)
CN (1) CN119317632A (cg-RX-API-DMAC7.html)
AU (1) AU2023253657A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247824A1 (cg-RX-API-DMAC7.html)
IL (1) IL316178A (cg-RX-API-DMAC7.html)
MX (1) MX2024012532A (cg-RX-API-DMAC7.html)
WO (1) WO2023201095A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
CN117965536A (zh) 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
EP4784753A2 (en) 2023-09-27 2026-08-05 Judo Bio Inc. Slc6a19-targeting modulatory nucleic acid agents
AU2024348221A1 (en) 2023-09-27 2026-04-30 Judo Bio Inc. Aminoglycosides for delivery of agents to the kidney
EP4784172A1 (en) 2023-09-27 2026-08-05 Judo Bio Inc. Polymyxins for delivery of agents to the kidney
CN117866028A (zh) * 2024-01-05 2024-04-12 苏州诺维康生物科技有限公司 一种医药中间体及其制备方法
WO2025213136A1 (en) * 2024-04-05 2025-10-09 Wave Life Sciences Ltd. Oligonucleotides comprising pn linkages and methods thereof
WO2026050243A1 (en) * 2024-08-26 2026-03-05 Korro Bio, Inc. Galnac conjugated oligonucleotides for rna editing
WO2026096688A1 (en) * 2024-10-30 2026-05-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015886A (en) * 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters

Also Published As

Publication number Publication date
AU2023253657A1 (en) 2024-11-14
KR20250004787A (ko) 2025-01-08
JP2025513847A (ja) 2025-04-30
IL316178A (en) 2024-12-01
WO2023201095A2 (en) 2023-10-19
CN119317632A (zh) 2025-01-14
US20250262235A1 (en) 2025-08-21
WO2023201095A3 (en) 2023-12-07
CA3247824A1 (en) 2023-10-19
EP4507700A2 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
WO2023201095A3 (en) Oligonucleotide compositions and methods relating thereto
AR112779A1 (es) Composiciones de nucleótidos y métodos relacionados
CA3179051A1 (en) Double stranded oligonucleotide compositions and methods relating thereto
MX2021012862A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
MX2023005326A (es) Composiciones de oligonucleótidos y métodos de las mismas.
MX2023015523A (es) Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogenicos.
CL2022002711A1 (es) Conjugados de anticuerpo-fármaco que comprenden agonistas de sting
CL2020002401A1 (es) Composiciones de arni de 17 b-hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas.
CO2024005352A2 (es) Composiciones de oligonucleótidos y métodos de estas
CO2018008196A2 (es) Dinucleótidos cíclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferón (sting) tales como cáncer
MX2018016253A (es) Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
DOP2024000081A (es) Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos
AR106135A1 (es) Moduladores de la expresión del sarcoma de la rata de kirsten (kras)
MX2022002532A (es) Métodos para generar y aislar neuronas de dopamina del mesencéfalo.
ECSP066268A (es) Inhibidores de la miostatina (gdf8) en combinación con corticoesteroides para el tratamiento de desórdenes neuromusculares
GT200500221A (es) Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan.
MX2022001767A (es) Construcciones de vesículas-oligonucleótidos antisentido (aso) extracelulares que se dirigen a transductor de señal y activador de la transcripción 6 (stat6).
DOP2024000225A (es) Composiciones y métodos para inhibir la expresión de mapt
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CL2022000262A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa (divisional de la solicitud no. 202100251)
CL2025003326A1 (es) Composiciones del agente de arni de la cinasa de repetición 2 rica en leucina
MX389545B (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
Robalo et al. Other-regarding preferences, in-group bias and political participation: An experiment
WO2023091644A3 (en) Hsd17b13-related double stranded oligonucleotide compositions and methods relating thereto
AR122534A1 (es) Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3